<DOC>
	<DOC>NCT02120950</DOC>
	<brief_summary>To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration</brief_summary>
	<brief_title>Aflibercept in Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Signed informed consent Men and women â‰¥50 years of age Diagnosis of symptomatic macular Polypoidal Choroidal Vasculopathy (PCV) in the study eye established by Indocyanine Green Angiography(ICGA) at the study center Prior use of intravitreal or subtenon corticosteroids in the study eye within 3 months prior to study entry Any prior use of intraocular anti Vascular Endothelial Growth Factor (antiVEGF)agents in the study eye, or systemic use of anti VEGF products within 3 months prior to study entry Prior macular laser treatment in the study eye including Photodynamic Therapy (PDT) History of allergy to fluorescein used in fluorescein angiography, iodine and/or indocyanine green. History of allergy to aflibercept, verteporfin, or their excipients.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PCV</keyword>
</DOC>